China-developed eye cancer drug wins FDA orphan drug designation
Late 2024 set the stage for a major oncology storyline that carried into 2025, as a new aptamer drug conjugate developed by Chinese researchers received FDA…
Late 2024 set the stage for a major oncology storyline that carried into 2025, as a new aptamer drug conjugate developed by Chinese researchers received FDA…